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This paper describes an efficient and reproducible screening method for identifying low
molecular weight compounds that bind to amyloid  peptides (A) peptides using electros-
pray ionization mass spectrometry (ESI-MS). Low molecular weight compounds capable of
interacting with soluble A may be able to modulate/inhibit the A aggregation process and
serve as potential disease-modifying agents for AD. The present approach was used to rank
the binding affinity of a library of compounds to A1-40 peptide. The results obtained show
that low molecular weight compounds bind similarly to A1-42, A1-40, as well as A1-28
peptides and they underline the critical role of A peptide charge motif in binding at
physiological pH. Finally, some elements of structure-activity relationship (SAR) involved in
the binding affinity of homotaurine to soluble A peptides are discussed. (J Am Soc Mass
Spectrom 2010, 21, 1506–1514) © 2010 Published by Elsevier Inc. on behalf of American Society
for Mass SpectrometryAlzheimer’s disease (AD) is an incurable, pro-gressive neurodegenerative condition leadingto a gradual decline in cognitive function. Intra-
cellular accumulation of neurofibrillary tangles consist-
ing of tau protein and extracellular deposition of senile
plaques composed of amyloid  peptides (A) repre-
sent histopathologic hallmarks of AD [1–3]. A is
considered to play a key role in AD pathogenesis [4]
and the amyloid cascade hypothesis [5] stipulates that
this results from the sequential - and -secretase
cleavage of the amyloid precursor protein (APP) [6, 7].
Several A variants, including A1-40 and A1-42,
produced by this amyloidogenic pathway are consid-
ered toxic under certain conditions. Nonpathologic low
concentrations of A are found in biological fluids
throughout life. Abnormal metabolism such as reduced
clearance or increased production leads to elevated A
concentration and aggregation [8]. At physiological pH,
soluble A mainly adopts a random coil conformation
[9] where peptides may interact to form intermolecular
-sheets leading to the production of intermediate
species such as oligomers, fibrils, and eventually
plaques [10, 11]. Whether or not the production of
oligomers and fibrils occurs through a common mech-
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doi:10.1016/j.jasms.2010.05.007anism is still debated [12]. Certain forms of oligomeric
A are believed to be toxic to neurons [13] while it has
been shown that A fibrils are harmful to cell mem-
branes and elicit inflammatory responses from glial
cells [14].
Proteoglycans (PGs) and glycosaminoglycans (GAGs)
found in amyloid deposits contribute to A fibril for-
mation by promoting the transition from a random coil
to a -sheet conformation [15, 16]. It was hypothesized
that by mimicking some GAGs structural properties,
low molecular weight (LMW) compounds could inter-
fere with the interaction of A with heparin sulphate
proteoglycans of the basement membrane during the
course of amyloid deposition [17]. One promising ther-
apeutic perspective consists in identifying LMW com-
pounds able to slow down or even stop these events in
amyloidogenic pathway [18]. It was postulated that
LMW compounds must first bind or interact with A to
interfere in the aggregation and fibril formation. Efforts
were invested in developing assays such as thioflavin T
fluorescence (ThT) [19] and circular dichroism (CD) [20]
to evaluate the interaction/binding of A with LWM
compounds. Very limited success has been achieved
primarily due to variability in different lots of synthetic
and recombinant A, both within and among laborato-
ries. Modifications in the A synthetic and purification
protocols may affect its conformational and fibrillogenic
properties [21, 22]. The presence of impurities may alter
A kinetics of aggregation [23] and different storage
conditions may also result in A chemical modifica-
tions [24]. Although serious efforts have been invested
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was highly desirable at this point.
Electrospray-ionization mass spectrometry (ESI-MS)
is an established technique for detecting noncovalent
protein/LMW molecules complexes [27–29]. Studies of
such complexes between specific LMW compounds and
A have been reported previously by other groups
[30–33] and us [34–36]. One debate in using ESI-MS is
whether or not the detected gas-phase complex main-
tains a structural resemblance to the solution-phase
complex. Although ESI-MS does not give insight into
the three dimensional structure of the complex, reason-
able agreements have been found between gas-phase
and solution-phase binding affinities [27]. However, in
source collisions can lead to the disruption of weakly-
bound complexes. On the other hand, droplet cooling
due to the evaporation of solvent can lead to an
apparent enhanced binding of the gas-phase complex
and the formation of higher order complexes which were
not pre-existing in the solution phase [37]. Nanospray-
ESI-MS has been shown to better represent the solution-
phase complex because smaller droplets undergo less
dissolvation [38, 39]. For these reasons, it is very diffi-
cult to determine absolute solution-phase binding ther-
modynamics from the mass spectrum. However, if care
is taken to maintain constant solution properties (pH,
salt content, and low analyte concentrations) as well as
constant ESI source parameters, the observed trends in
binding between analytes and the target peptide ob-
served in ESI mass spectra will be consistent with those
in solution [40].
The scope of this study is focused on the application
of an efficient and reproducible moderate throughput
ESI-MS screening method for the ranking of the binding
affinity (BA) of a library of LMW compounds to A1-42,
A1-40, and A1-28. The role of side-chain charge is
investigated by substitution of charged amino acids by
neutral amino acids on the A1-28 sequence. Recent
literature reported the effect of pyroglutamate-modified
N-terminal truncated A (A3pE-40) to influence the
oligomerization process [41] and to induce learning
impairment as well as neuronal apoptosis [42]. Due to the
increasing interest, we also investigated the BA of LMW
compounds to this peptide. Finally, we discuss the peptide-
binding characteristics of homotaurine, a natural product [43,
44] for the potential treatment of AD [45].
Experimental
Materials
A1-28, A1-40, A1-42, and A3pE-40 peptides were
purchased from rPeptide (Bogart, GA) and three addi-
tional peptides were synthesized in-house (Figure 1).
LMW compounds were purchased from commercial
sources or synthesized in-house (Table 1). Stock solu-
tion (50 M) of each peptide was prepared in 0.1%
trifluoroacetic acid (TFA, in deionized H2O), which
helps minimize peptide self-assembly by maintainingthe N-terminal part as an -helix [46, 47]. Each stock
solution was then sonicated for 5 min. To determine the
binding affinity (BA) of LMW compounds, a stock
solution of A peptide was mixed with a compound
solution in deionized H2O to obtain a test solution with
final concentrations of 30 M and 150 M for the
peptide and the compound, respectively [34, 36]. The
pH of the test solution was adjusted to 7.4  0.2 using
0.1% NaOH and a Beckman (Mississauga, Canada) 35
pH meter equipped with a Corning semi-micro combi-
nation pH electrode.
ESI-M Analysis
ESI-MS measurements were performed on a Waters ZQ
4000 mass spectrometer equipped with a Waters 2795
sample manager (Waters, Manchester, England). Mass-
Lynx 4.1 was employed for data processing and analy-
sis. The sample solutions were injected in the ESI-MS
using a mobile phase composed of 95% H2O and 5%
ethanol at a flow rate of 150 L · min1. A 2 L air gap
was drawn before and after the compound-peptide
mixture so that the mobile phase was not in contact
with the sample. The desolvation temperature was set
to 150 °C while the source temperature was maintained
at 90 °C. The desolvation and nebulization gases were
both set to 300 mL/min. The cone and capillary volt-
ages were kept at 18 V and 3.2 kV, respectively. All
mass spectra were sums of 300 scans (0.9 scan/s,
inter-scan delay of 0.1 s) from 100 to 2000 (m/z) in the
positive mode.
Results and Discussion
A1-40 and A1-42 peptides share an identical amino
1                           10                              20                       28                                    40 
-     -   +    -          -             +               - -            + 
H2N-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA-OH   
Aβ1-42 (4514Da)
-     -   +    -          -             +               - -            +  
H2N-DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-OH 
Aβ1-40 (4330Da)
-     -   +    -         -              +               - -            + 
H2N-DAEFRHDSGYEVHHQKLVFFAEDVGSNK-OH
Aβ1-28 (3263Da)
                             -             -               -     
H2N-GASFGHASGYEVHHQELVFFAESVGSNS-NH2 
all (-) peptide (2950Da)
                    +                              +                              + 
H2N-GASFRHASGYSVHHQKLVFFASAVGSN K-NH2
all (+) peptide (2989Da)
                   +    -          -             +              -  -            + 
        pyro-FRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV-OH 
Aβ3pE-40 (4126Da)
Figure 1. Peptides used in the study. The numbers on top
represent the amino acid number in the sequence. The plus “”
and minus “–” signs represent the positive or negative charge,
respectively in its side chain at physiological pH. Each peptide
sequence is followed by its name and molecular weight in
parentheses.acid (AA) sequence except for two AA residues, Ile and
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No. Structurea M.W. Name(s) [CAS]
1 237.3 3-Cyclohexylamino-2-hydroxy-1-propanesulfonic acid; CAPSO
[73463-39-5]
2 225.3 3-(1-Hydroxy-2-pentyl)amino-1-propanesulfonic acid [720699-42-3]
3 139.2 3-Amino-1-propanesulfonic acid; homotaurine; Vivimind [3687-18-1]
4 165.2 3-Amino-3-phenylpropanoic acid [103-01-5]
5 139.1 3-Aminopropyl-1-phosphonic acid [13138-33-5]
6 103.1 4-Aminobutyric acid; GABA [56-12-2]
7 73.1 n-Butylamine [109-73-9]
8 138.2 1-Butanesulfonic acid [2386-47-2]
9 140.2 3-Hydroxy-1-propanesulfonic acid [15909-83-8]
10 204.2 1,3-propanedisulfonic acid; Eprodisate; Kiacta [13881-91-9]
11 125.2 2-Aminoethanesulfonic acid; taurine [2386-47-2]
12 153.2 4-Amino-1-butanesulfonic acid [14064-34-7]
13 167.2 5-Amino-1-pentanesulfonic acid [37043-68-8]
14 181.2 6-Amino-1-hexanesulfonic acid [72372-71-5]aOnly non-salt forms are given. Some compounds were sodium salt forms.
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A1-28 peptide is a C-terminal-truncated version of the
A1-40/42 peptides containing only the first 28 AA
residues from the N-terminal. The C-terminal part of
the A1-40/42 peptides (AA 29–40/42) is the hydro-
phobic part. All charged or polar side chains are located
in the first 28 residues of the N-terminal. The charge
distribution in the peptides has a unique pattern: a
positive charge following two negative charges at pH
7.4  0.2 (assuming that histidines remain uncharged
under such conditions). The charge motif is repeated
three times from residue 1 (D) to residue 28 (K). Under
Figure 2. Binding profiles of Compounds 1–4 t
with peak clusters due to the protonated pep
Table 2. Binding affinity (eq 1) for Compounds 1–4 with A1-




1 54  3 49  1 49  1
2 38  2 43  2 41  4
3 28  3 33  1 33  3
4 14  1 13  1 9  1compound:peptide complex.experimental conditions at physiologic pH, the mass
spectra of the three peptides (A1-42, A1-40, and
A1-28) show typical peaks corresponding to species
having four and five positive charges. In certain cases, a
three positive charge region is visible as well. Each
charged species appears as a peak cluster due to the
various number of sodium ions associated to the pep-
tide. Consequently, when a LMW compound is bound
to a peptide, the noncovalent complex also appears as a
peak cluster at the corresponding m/z ratio, due to the
association of the complex with various numbers of
sodium ions. To evaluate the BA of a compound to the
A peptide, the following equation was used:
BA(%)
 complex peaks height
 (peptide peaks heights
 complex peaks heights)
 100 (1)
In eq 1, the sums are over all ionic species present in the
mass spectrum for the complex or peptide (all peaks
have the same widths). For purposes of reproducibility,
the average binding (mean  SD) was calculated from
1–42. 5 and 4 charge regions denoted, along
(0:1), 1:1 compound:peptide complex and 2:1o A
tide
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10% was required. Other groups have developed meth-
ods to calculate an association constant (KA) [39, 48, 49].
Although more accurate, the calculation of KA can be
time-consuming for a first-line screening method. It is
worth mentioning that our assay uses much less com-
pound and peptide to observe complex formation than
in a method previously described [32]. Previously, we
have shown [34] that the maximum BA between a given
compound and the A1-40 peptide rises from pH 1 to
approximately pH 6 and then decreases with further
increase of pH. Hence, the maximum BA is close to the
Figure 3. Binding profiles of Compounds 1–4
denoted, along with peak clusters due to the pro
Table 3. Binding affinity (eq 1) for Compounds 1–4 with
peptides of different charge motif
Compound no.
BA (%)
A1-28 (native) all () all ()
1 49  1 35  2 30  2
2 41  4 33  3 24  1
3 33  3 16  2 0
4 9  1 6  1 0and 2:1 compound:peptide complex.physiological pH. In this assay, the A1-40 peptide was
selected over the A1-42 and A1-28 peptides for two
reasons: first, the A1-40 peptide is less prone to
aggregation and has a better water solubility than the
A1-42 peptide [11] and second, it contains a C-
terminal hydrophobic region (absent in the A1-28
peptide), which makes it more physiologically relevant.
To further justify the selection of the A1-40 peptide for
this assay, it was required to verify if this peptide could
differentiate the binding strength of various com-
pounds and if the BA ranking order remained consis-
tent whichever peptide (A1-28, A1-40, or A1-42)
was used. Table 2 summarizes the binding results
between representative compounds and the three A
peptides.
For visual examination of binding complexes, Figure
2 compares the binding profiles of the four selected
compounds to the A1-42 peptide. The m/z region from
900 to 1125 contains the peak-clusters of the peptide and
the complexes bearing five positive charges (5 region).
The m/z region from 1125 to 1400 contains the species
having four positive charges (4 region). The m/z
he all () peptide. 5 and 4 charge regions
ed peptide (0:1), 1:1 compound:peptide complexto t
tonat
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charges (3 region) is not shown on the spectra. On all
mass spectra, the peak-clusters centered approximately
at m/z  925, 1151, and 1526 (not shown) are the free
peptides having 5, 4, and 3 charges, respectively.
In each region, to the right side of the free peptide peak
cluster are the 1:1 compound-peptide complex (first
peak cluster), the 2:1 compound-peptide complex (sec-
ond peak cluster), and the 3:1 compound-peptide com-
plex (third peak cluster). This observation indicates, at
least in some cases, that more than one molecule of a
compound can bind to one peptide ion. Employing the
intensities of each peak in eq 1 allows the calculation of
BA. Compounds in Table 2 represent four different
categories (strong, BA  45%; moderate, 35  BA 
45%; weak, 20  BA  35%, and non-binding, BA 
20%). One aspect of ESI that hinders the quantitative
assignment of the BA in solution is the tendency to form
noncovalent complexes in the gas-phase during the
electrospray process. The compounds in Table 2 are all
structurally similar and thus differences between solu-
Figure 4. Binding profiles of Compounds 1–4
denoted, along with peak clusters due to the pro
and 2:1 compound:peptide complex.tion and gas-phase behavior should also be conservedacross the compound library, making comparisons
meaningful.
As shown in Table 2, the BA ranking order remains
the same for each given compound to all three peptides.
Furthermore, the “absolute binding affinity” (as mea-
sured in binding percentage) for a specific compound is
similar when tested against all three peptides. These
observations indicate that the C-terminal hydrophobic
part of the A peptide does not play a significant role in
binding these LMW compounds, suggesting therefore
that the N-terminal part is mostly responsible for the
noncovalent binding. The noncovalent complex forma-
tion occurs through dipole–dipole or charge–charge
interactions [50]. In this assay, we have chosen to use
A1-40 as the peptide for screening purposes since it is
the least expensive.
During method development, another important
consideration was given to ensure that these low struc-
tural complexity compounds were binding specifically
to A peptides and not to any peptide in general. At
physiologic pH, the N-terminal sequence of the A
he all () peptide. 5 and 4 charge regions
ed peptide (0:1), 1:1 compound:peptide complexto t
tonatpeptide possesses a specific charge motif, which may
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compounds. To test this hypothesis, two peptides (all
(), all (), each having 28 AA residues; see Figure 1)
were synthesized and studied for their binding behav-
ior. At physiologic pH the “all () peptide” has three
negatively charged residues in the sequence and no
positive charges (except for the N-terminal residue) and
the “all () peptide” has three positively charged
residues. Table 3 compares the BA of Compounds 1–4
with these two peptides and A1-28. When comparing
the BA of Compounds 1–4 with all three peptides
Figure 5. Binding profiles of Compounds 1–4 t
along with peak clusters due to the protonated p
Table 4. Binding affinity (eq 1) for Compounds 1–4 with
A3pE-40 and A1-40 in 20% ethanol
Compound no.
BA in 20% ethanol (%)
A1-40 A3pE-40
1 57  1 49  1
2 52  1 39  1
3 37  1 30  2
4 22  1 15  1compound:peptide complex.having 28-AA residues, the most striking observation is
that none of them bind significantly to the all ()
peptide (Figure 3). One important feature of the mass
spectra is the absence of sodium cluster peaks for this
system because there are no side chains charged nega-
tively under experimental conditions. In the all ()
peptide, all these AA residues have been substituted by
neutral ones; thus, there may be one (or a very few)
sodium cations that are bound to the species present on
these mass spectra.
Figure 4 shows the binding profile of the four
compounds to the all () peptide. The peak-cluster
centered at m/z 755 represents the free peptide having
four positive charges, whereas the one at m/z 999 is the
3 charged species of the peptide. In this case, the BA
was decreased by at least 25% with all four compounds
compared with the native peptide. Interestingly, the
decrease of the BA is not proportional to the lower
number of negative charges in the peptide. When
comparing observations made with the all () peptide,
it may be concluded that binding of these compounds is
A3pE-40. 5 and 4 charge regions denoted,
e (0:1), 1:1 compound:peptide complex and 2:1o the
eptid
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chains in the A peptide.
The BA of the A1-40 peptide with Compounds 1–4
was compared with their binding with the A3pE-40
peptide under exactly same conditions. A3pE-40 was
shown to be very amyloidogenic and could potentially
initiate the amyloid aggregation process. Due to the low
solubility of A3pE-40 in aqueous media, experiments
for both peptides were performed in a mixture of water
(80%) and ethanol (20%). The data are summarized in
Table 4 and the mass spectra are given in Figure 5. As
shown in Table 4, the BA with the A1-40 peptide
increases by 5% to 10% for Compounds 1–4 when the
solvent contains 20% ethanol. Their BA with the
A3pE-40 peptide was 5% to 10% lower compared to
A1-40, but the ranking order stayed the same. The
lower BA with the A3pE-40 peptide might be due
either to removal of two negative charges from the
N-terminal or to disappearance of a charge motif after
the N-terminal truncation of A1-40 peptide.
Effort was also directed to the structure–activity
relationship (SAR) for binding of the A1-40 peptide
with LMW compounds. Homotaurine (Compound 3,
Vivimind) aims at targeting soluble A peptide and
was used as a reference point for comparing the effect of
each component in the structure: the amino group, the
sulphonate group, and the alkyl spacer in between.
Table 5 reports the effect of different substitutions on
the sulfonic group. None of the substitutions shown in
Table 5 is advantageous to maintain BA. Only the
phosphonate substituent retained significant binding. It
is important to mention here that GABA, a bioisostere
of homotaurine and an important neurotransmitter
present in the human brain, does not bind at all to
soluble A1-40 peptide. Table 6 reports the effect of
amine substitution of Compound 3. Again in this case,
none of the reported substitutions was advantageous to
maintain BA. Only methyl substitution was able to
preserve some binding. Eprodisate (Compound 10), an
investigational clinical drug candidate targeting serum
amyloid A [51], is selective for this peptide and does not
Table 5. Effect of replacing the sulfonic group on the binding
affinity (eq 1) with A1-40
Compound no. H2N-(CH2)3-R BA to A1-40 (%)
3 -SO3H 33  1
5 -PO3H2 24  1
6 -CO2H 0
7 -CH3 0
Table 6. Effect of replacing the amino group on the binding
affinity (eq 1) with A1-40
Compound no. R-(CH2)3-SO3H BA to A1-40 (%)
3 -NH2 33  1
8 -CH3 26
9 -OH 0
10 -SO3H 0bind to the A1-40 peptide. Finally, the length of the
alkyl spacer was investigated using five different chain
spacers tested against the A1-40 peptide (Table 7). The
alkyl spacer does not play a significant role in main-
taining BA to the A1-40 peptide, although it seemed
that the homotaurine three-carbon spacer between
amino and sulphonate groups was optimal. The lack of
sensitivity of BA to the length of the carbon spacer
might be due to the flexibility of the linear structure in
such simple compounds. Altogether, this information
on the binding components of homotaurine shows that
even though it is not a strong binder to A peptides, it
contains key elements to be considered as an anti-
amyloid agent. The mechanism of action of homotau-
rine for the treatment of AD has been extensively
studied, in vitro and in vivo, and results will be
reported separately.
Conclusion
An efficient and reproducible ESI-MS binding assay
was developed for semiquantitative evaluation of the
binding affinity of LMW compounds to A peptides.
The assay proved to be consistent on the binding
affinity (BA) ranking from one peptide to another when
comparing the noncovalent complexes formed with the
same set of four compounds with A1-28/40/42. This
allowed the use of peptide A1-40 in this first-line
screening assay. It was demonstrated that mutation or
scrambling of the A peptide sequence affects the BA of
the four targeted LMW compounds with the peptides.
A similar effect was observed when the four LMW
compounds were tested against A3pE-40. The results
indicate that the binding between A and a LMW
compound is likely through charge–charge interaction,
and the negative charge motifs in the peptide are
important to such. The results obtained using this assay
indicated that homotaurine contains the necessary mo-
lecular properties for its binding to the soluble A
peptide, and could interfere with the amyloidogenic
cascade. In this study, BA obtained with the assay can
be used as the first-line screening to select LMW com-
pounds for further testing in biological assays.
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